Notice of Intent to Sole Source- Investigative Services Police Department (Multiple Locations)
ID: FDANOI10282024Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFFOOD AND DRUG ADMINISTRATIONRockville, MD, 20841, US

NAICS

Police Protection (922120)

PSC

SUPPORT- PROFESSIONAL: OTHER (R499)

Original Source

https://sam.gov/opp/2298f13bc6e847c5824bdcaa4879b816/view
Timeline
  1. 1
    Posted Oct 28, 2024, 12:00 AM UTC
  2. 2
    Updated Oct 28, 2024, 12:00 AM UTC
  3. 3
    Due Nov 12, 2024, 3:00 PM UTC
Description

The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), intends to issue sole source contracts for investigative services with several police departments, including East Providence, North Providence, Virginia, West Virginia, Hopkinton, and Kentucky. The objective of this procurement is to engage these law enforcement agencies for specialized investigative work, with each department receiving an individual contract for a period of performance set for 12 months from the award date. This initiative falls under NAICS code 922120 and is authorized by statute 10 USC 2304 (c)(5), indicating that competitive proposals are not being solicited. Interested firms must submit their capability statements by 10:00 a.m. EST on November 12, 2024, to Nina Montgomery at nina.montgomery@fda.hhs.gov to be considered for this opportunity.

Point(s) of Contact
Nina Montgomery
(240) 402-8086
nina.montgomery@fda.hhs.gov
Files
Title
Posted
Notice of Intent_10282024.pdf
Oct 29, 2024, 1:08 AM UTC
The Food and Drug Administration (FDA) is initiating sole source contracts for investigative work with several police departments, including East Providence, North Providence, Virginia, West Virginia, Hopkinton, and Kentucky. Each department will receive an individual contract, and the period of performance is set for 12 months from the award date. This procurement falls under NAICS code 922120 and is authorized by statute 10 USC 2304 (c)(5), indicating the absence of competitive proposals for this solicitation. Interested firms must express their capability within 7 days to be considered. The notice will close on November 12, 2024, at 10 am EST, with responses directed to Nina Montgomery via email. This document underscores the FDA's strategy to streamline procurement processes while engaging specific law enforcement agencies for specialized services.
Lifecycle
Title
Type
Notice of Intent to Sole Source- Investigative Services Police Department (Multiple Locations)
Currently viewing
Special Notice
Similar Opportunities
FDA NCTR On-Site Pathology Services
Buyer not available
The U.S. Food and Drug Administration (FDA) is preparing to solicit comprehensive on-site animal pathology services for its National Center for Toxicological Research (NCTR) to support its research programs aimed at public health protection. The required services will encompass a variety of pathology support tasks, including necropsies, histopathology, and specialized techniques such as immunohistochemistry and respiratory pathology, as dictated by research protocols from Principal Investigators. This opportunity is significant for businesses in the professional, scientific, and technical services sector, with the solicitation number 75F40125R00059 expected to be released around April 30, 2025, and a closing date set for 30 days post-release. Interested parties should monitor SAM.gov for updates and can contact Tim Walbert at timothy.walbert@fda.hhs.gov or 870-543-7267 for further information.
“Brand Name or Equal” Emulate Inc., Chip-R1 Rigid Chips, plus Preventive Maintenance and Repair Service on Emulate Modules
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified vendors to provide "Brand Name or Equal" Emulate Inc., Chip-R1 Rigid Chips, along with preventive maintenance and repair services for Emulate Modules. The procurement aims to support the National Center for Toxicological Research (NCTR) in evaluating a novel brain-chip system designed to assess neurotoxicity induced by CD19 CAR T-cells, which is critical for advancing research in neurotoxicology. Interested small businesses and other vendors capable of meeting the specified technical requirements are encouraged to submit capability statements by April 28, 2025, at 1:00 PM Central Time, to Warren Dutter at warren.dutter@fda.hhs.gov. This sources sought announcement does not constitute a solicitation for proposals, and no contract will be awarded from this announcement.
IDIQ for the purchase of human induced pluripotent stem cell-derived cells
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking to award a sole-source contract for the procurement of human induced pluripotent stem cell-derived cells from Fujifilm Cellular Dynamics. This acquisition aims to support a research program focused on microphysiological systems (MPS), which are critical for advanced in-vitro models used in drug safety and efficacy assessments. The cells, including cardiomyocytes, neurons, astrocytes, and hepatocytes, will be cryopreserved and utilized by FDA scientists at the Center for Drug Evaluation and Research, ensuring continuity in ongoing projects due to the established partnership with Fujifilm. Interested vendors may submit capability statements within 15 days of the notice, with the response deadline set for 10 AM EST on May 2, 2025; inquiries should be directed to Telisha Wilson at telisha.wilson@fda.hhs.gov.
PRIMO Software Licensing
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide PRIMO Software Licensing and Maintenance Support Services. The procurement involves supplying 21 PRIMO software licenses for a base year, with two additional option years, to ensure the continuous operation of the FDA's CFSAN CAEMS system. This software is crucial for pharmacovigilance and regulatory compliance, enhancing the FDA's capabilities in monitoring food safety. Interested parties must submit their quotes by August 26, 2024, and are encouraged to contact Roosevelt Walker at roosevelt.walker@fda.hhs.gov for further details. The contract will be awarded as a firm-fixed-price purchase order, emphasizing compliance with federal acquisition regulations and accessibility standards.
Drug Manufacturing and Formulation Contract II
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified contractors for the Drug Manufacturing and Formulation Contract II (DFMC II) to support the manufacturing and documentation processes for investigational drug products. The primary objective of this procurement is to develop dosage forms of small molecule drug candidates for clinical trials and preclinical studies, ensuring compliance with Good Manufacturing Practices (cGMP) and regulatory standards set by the FDA and other governing bodies. This initiative is crucial for maintaining high standards in drug development and research support, facilitating the safe and effective delivery of investigational products. Interested parties should contact Dr. William H. M. Etti at William.Etti@nih.gov or call 301-402-4422 for further information regarding this opportunity, which includes a partial small business set-aside and is expected to be awarded under an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract framework.
Illumina MiSeq Instrument Service Agreement
Buyer not available
The U.S. Food and Drug Administration (FDA) is conducting market research to identify small business sources capable of providing a service agreement for the Illumina MiSeq instrument, which is essential for the National Center for Toxicological Research (NCTR). The procurement involves a preventative maintenance and corrective maintenance service agreement, including scheduled on-site visits, unlimited technical support, and adherence to OEM specifications. This service is critical for ensuring the reliability of ongoing research at the NCTR facility in Jefferson, Arkansas. Interested parties must submit their capability statements by April 30, 2025, to Nick Sartain at nick.sartain@fda.hhs.gov, referencing NCTR-2025-128267.
HemaComply Software Maintenance and Support Services
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a firm-fixed-price contract for HemaComply Software Maintenance and Support Services on a sole-source basis to Hema Terra Technologies LLC. The contract aims to provide ongoing maintenance and support for HemaComply software applications, which are critical for ensuring compliance with FDA regulations in blood donor operations and managing electronic records for NIH patients and blood donors. This software is essential for the Department of Transfusion Medicine's operations, which include the collection of blood and blood components for biomedical research and patient treatment. Interested parties are invited to submit capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by April 30, 2025, at 6:30 AM EST, as this is not a request for quotation and no solicitation will be issued.
Jefferson Laboratories On-Site Laboratory Equipment Maintenance, Repair, and Fabrication Services
Buyer not available
The Department of Health and Human Services, through the Food and Drug Administration (FDA), is seeking proposals for on-site laboratory equipment maintenance, repair, and fabrication services at the National Center for Toxicological Research (NCTR) in Jefferson, Arkansas. The selected contractor will be responsible for maintaining and repairing a variety of laboratory instruments, ensuring compliance with safety protocols and standard operating procedures, while also providing preventive maintenance and specialized equipment design services. This contract is crucial for supporting ongoing toxicological research, as much of the equipment requires maintenance beyond manufacturer warranties. Interested parties should submit their proposals, adhering to the instructions and evaluation criteria outlined in the solicitation, with inquiries directed to Suzanne Martella at suzanne.martella@fda.hhs.gov or by phone at 870-543-7540. The contract will be awarded as a firm fixed-price agreement covering a base year and four option years, with detailed requirements specified in the solicitation documents.
Notice of Intent to Award a Sole Source BPA
Buyer not available
The Defense Health Agency (DHA) intends to award a Sole Source Blanket Purchase Agreement (BPA) to Broughton Pharmaceuticals, LLC for the procurement of specialty pharmaceuticals, including oral, injectable, and inhalation forms. This procurement is being conducted under FAR 13.501(a)(1), indicating that no competitive solicitations will be available at this time, and it aims to ensure the military healthcare system has access to essential specialized health services and products. Interested parties may submit capability statements by April 30, 2025, at 2:00 PM EST, to the designated contacts, Oneil Sharpe and Mrs. Faatalivale M. Te’o-Lewis, for consideration regarding potential competitive procurement, although the final decision will rest with the government.
Research and Development of the FDA ARGOS System
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified vendors for the research and development of the FDA ARGOS System, as outlined in a Sources Sought Notice. The primary objective is to enhance the FDA ARGOS database and develop bioinformatics and artificial intelligence tools to analyze genetic data, thereby improving public health preparedness and regulatory processes related to medical countermeasures against infectious diseases. This initiative is crucial for advancing diagnostic capabilities through Next Generation Sequencing (NGS) technology, which can identify microbial pathogens efficiently and accurately. Interested parties must submit their responses, including a Vendor Feedback Form, to Nicholas Bisher and Kimberly Pennix by May 2, 2025, at 2:00 PM EST, as no solicitation is currently available.